Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)
Clinical trial NCT03711578 · COMPLETED
Trial details
- NCT number
- NCT03711578
- Sponsor
- Rhizen Pharmaceuticals SA
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-25
- Primary completion
- 2020-06-16
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.